Format

Send to

Choose Destination
Arthritis Rheum. 1989 May;32(5):638-42.

Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin: clinical and in vitro studies.

Author information

1
Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.

Abstract

Two anemic patients with rheumatoid arthritis were treated with recombinant human erythropoietin (EPO) for 5 months. Both patients showed significant increases in hematocrit, red cell volumes, and marrow erythroid and megakaryocyte progenitor cells. No significant toxic effects from EPO were observed. These data indicate that EPO may be effective in overcoming the pathogenetic factors that limit erythropoiesis in rheumatoid arthritis.

PMID:
2719734
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center